Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Gain-in-function mutations in RAS genes occur in ~30% of human cancers, leading to constitutive RAS protein activation.
• RAS-driven signaling pathways, like RAS-mitogen activated protein kinase, promote cancer cell proliferation and metastasis.
• RAS oncogenesis contributes to immune evasion by upregulating PD-L1, downregulating MHC molecules, and altering cytokine expression, fostering an immunosuppressive tumor microenvironment.

Purpose of the Study:

• To review the potential of RAS inhibitors to overcome resistance to current cancer therapies.
• To explore how RAS inhibitors can enhance the efficacy of checkpoint immunotherapy.
• To highlight the role of RAS inhibitors in modulating the tumor microenvironment and improving anti-tumor immunity.

Main Methods:

• Literature review of studies on RAS mutations, oncogenesis, and immunotherapy.
• Analysis of mechanisms by which RAS-driven tumors evade immune surveillance.
• Examination of preclinical and clinical data on RAS inhibitors and their combination with checkpoint inhibitors.

Main Results:

• RAS-driven tumors create an immunosuppressive microenvironment, leading to resistance to checkpoint immunotherapy.
• RAS inhibitors show potential in weakening cancer cell immune evasion.
• Combining RAS inhibitors with checkpoint immunotherapy may broaden anti-cancer activity and improve patient survival.

Conclusions:

• RAS inhibitors represent a promising therapeutic strategy for RAS-driven cancers.
• Targeting RAS could enhance the effectiveness of existing immunotherapies.
• Further research into RAS inhibitors is crucial for improving outcomes in patients with RAS-driven malignancies.